Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.61 |
| ▸ | NPY1R | P25929 | 2/20 | 0.57 |
| ▸ | NPY2R | P49146 | 2/20 | 0.57 |
| ▸ | NPY4R | P50391 | 2/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27204558 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL27164800 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL30772333 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL31468793 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL31593305 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL31593388 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29578372 | 0.99 | GHSR (0.62) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL3384748 | 0.99 | GHSR (0.62) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL27702662 | 0.99 | GHSR (0.62) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL30866234 | 0.98 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030099-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | GHSR 2961/4885NPY1R 3454/4885NPY2R 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.